These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 23641363)
1. Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Pfeiffer MM; Burow H; Schleicher S; Handgretinger R; Lang P Front Oncol; 2013; 3():99. PubMed ID: 23641363 [TBL] [Abstract][Full Text] [Related]
2. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. Shi X; Li M; Cui M; Niu C; Xu J; Zhou L; Li W; Gao Y; Kong W; Cui J; Hu J; Jin H Am J Cancer Res; 2016; 6(3):600-14. PubMed ID: 27152238 [TBL] [Abstract][Full Text] [Related]
4. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634 [TBL] [Abstract][Full Text] [Related]
5. The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. Ponath V; Frech M; Bittermann M; Al Khayer R; Neubauer A; Brendel C; Pogge von Strandmann E Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33023028 [TBL] [Abstract][Full Text] [Related]
6. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Wu X; Tao Y; Hou J; Meng X; Shi J Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050 [TBL] [Abstract][Full Text] [Related]
7. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088 [TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331 [TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781 [TBL] [Abstract][Full Text] [Related]
11. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma. Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC Front Oncol; 2022; 12():1009089. PubMed ID: 36185276 [TBL] [Abstract][Full Text] [Related]
12. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103 [TBL] [Abstract][Full Text] [Related]
13. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells. Schcolnik-Cabrera A; Domínguez-Gómez G; Dueñas-González A Am J Blood Res; 2018; 8(2):5-16. PubMed ID: 30038842 [TBL] [Abstract][Full Text] [Related]
15. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD Front Immunol; 2020; 11():40. PubMed ID: 32082316 [TBL] [Abstract][Full Text] [Related]
16. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760 [TBL] [Abstract][Full Text] [Related]
18. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors. Whitmore MA; Li H; Lyu W; Khanam S; Zhang G Front Immunol; 2022; 13():874706. PubMed ID: 35529861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]